Processa Pharmaceuticals Q1 net loss widens to $3.38 million

Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc.

PCSA

0.00
  • Processa Pharmaceuticals posted a net loss of USD 3.38 million for quarter ended March 31, 2026, widening from USD 2.83 million a year earlier.
  • Operating loss widened to USD 3.33 million as research and development costs rose to USD 1.81 million and general and administrative expenses increased to USD 1.52 million.
  • Revenue remained absent, with management stating it has no revenue under contract or immediate sales prospects.
  • Cash and cash equivalents totaled USD 1.7 million at March 31, 2026, and management said it expects to need additional capital in second quarter 2026.
  • Phase 2 NGC-Cap breast cancer study had enrolled and dosed 20 patients for first interim analysis, expected to be completed in first half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Processa Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-021721), on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.